Guilford Street Laboratories

Really proud of this one, some of the first work I did during my PhD a “few” years back. Decanoic acid (C10) has been demonstrated to act through PPARg to increase mitochondial content, improve antioxidant status and has antiseizure activity (likely due to the above). But we’ve always wondered, if it’s acting through PPARg - the first P in PPAR stands for peroxisome - then does C10 alter peroxisomal metabolism in concert with its effect on the mitochondria. In short, yes. Our preliminary work here indicates a significant boost to VLCFA beta oxidation capabilities in a neural-like cell model following C10 exposure, linked to increased peroxisomal proliferation. Whilst this makes sense, it was really cool to demonstrate for the first time. It also begs the question - fatty acids to treat disorders of fatty acid metabolism? Big thanks to Vitaflo for supporting this work! Simon Heales Simon Eaton Tricia Rutherford Peter Clayton #MCFA #C10 #peroxisome #peroxisomaldisease #metabolism https://lnkd.in/eVn7PGTu

We are thrilled to announce that GSL will be attending The Parkinson's Disease Therapeutics Conference (PDTC) in New York City this October! 🗽 The PDTC, organized by The Michael J. Fox Foundation for Parkinson's Research, is the world's only conference dedicated exclusively to Parkinson's disease drug development. This year marks the 16th Annual PD Therapeutics Conference, scheduled for October 17, 2024. 🧬✨ If you're planning to attend and would like to connect, please reach out to us! We are eager to discuss potential collaborations, share insights, and explore new frontiers in Parkinson's disease research. Let's make strides together toward a cure! 💡🤝 #PDTC2024 #ParkinsonsDisease #GSL #MichaelJFoxFoundation #DrugDevelopment #ScientificConference #Research #Collaboration 👉 Book a meeting with us: Info@guilfordstreetlabs.com

The power of mass spectrometry and machine learning: 8 protein biomarkers that can accurately diagnose and predict the onset of Parkinson's disease up to 7 years before the onset of symptoms. At GSL, we are working hard to develop this outstanding achievement in next-generation diagnostics in to a commercially available test. Speak to the team for more information! #parkinsonsdisease #biomarkers #machinelearning #proteomics #massspectrometry #diagnostics https://lnkd.in/dY2xKxwr

James Moon and Mark Westwood showcased #1CMR today as part of our upcoming #ConfidenceSuite launch. The demo was a success, with attendees excited to see how this tool will revolutionise cardiac diagnostics. If you'd like to be in the know, get in touch with the team: partnership@mycardium.com #SaaS #cardiology #healthcareinnovation

📢 Exciting News! 📢 Our very own Professor Kevin Mills has been making waves in the media, recently being interviewed by several prominent news outlets, including ITV News. 🎥 Check out the interview attached! Thanks to the incredible work of our academic partners, we are thrilled to share a groundbreaking advancement in medical diagnostics. They have developed a revolutionary blood test that, when combined with artificial intelligence (AI), can predict Parkinson's disease up to seven years before symptoms appear. This is a major step forward in diagnosing the condition and could significantly change the way we approach Parkinson's disease. At GSL, we are incredibly excited about the potential of this innovative test and look forward to bringing this to point of care in the near future. This is just one example of how cutting-edge research and technology are transforming healthcare and improving lives. Stay tuned for more updates on our journey to revolutionize medical diagnostics! https://lnkd.in/evvCWZN8 #GSL #ParkinsonsDisease #AI #MedicalResearch #GSL #FutureOfMedicine #ITVNews

Front page news!

GSL’s very own Kevin Mills has been interviewed by the bbc this week about the impressive breakthrough in Parkinson’s diagnosis!

Game changing work coming out of the lab of our CSO - Professor Kevin Mills. Hypertrophic cardiomyopathy is one of the leading causes of sudden cardiac death in children and this test has the potential to identify at risk patients earlier, allowing life saving treatments to take place. At GSL, we are working hard to make this test widely available to the public and healthcare providers - speak to the team today if you’d like to hear more. #hypertrophiccardiomyopathy #suddencardiacdeath #biomarkers #diagnostics #HCM https://lnkd.in/eqzjN3TQ

At GSL, we are proud to be a spin-out from one of the worlds leading universities. Great to see that once again UCL are being recognised for their excellence in academia and research. #UCL #spinout

Well done to Dr Wendy Heywood talking about the disease mechanisms involved in Fabry disease. Asking why and how, lyso-lipids effect cellular metabolism.